Qi Zhou

This record under the name Qi Zhou appears to combine several distinct lines of work, most centrally the formulation and toxicity of inhaled antibiotics (such as polymyxin and colistin) for treating drug-resistant lung infections, including studies of how these drugs damage lung cells. Other publications attributed to this name cover unrelated areas such as nanoparticle-based sensors, laryngoscope devices, dairy cow nutrition, and materials science, suggesting the name may represent multiple researchers or collaborators across fields. Prospective students should verify which specific line of work and lab this corresponds to before assuming a single coherent research program.

Publication output has fluctuated over the last decade, rising to a peak around 2020-2021, dipping in 2023, and partially recovering in 2024-2025, without a clear sustained growth or decline trend.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026